Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RVMD · as of Mar 31, 2025
Ownership Breakdown
297
Institutional Holders
▼ 1 vs Q4
$6.83B
Total Inst. Value
▼ $1.62B vs Q4
212.60M
Shares Outstanding
freeFloat 89.54%
192.47M
13F Shares Held
▼ 598,500 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RVMD largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 16.61M | 8.83% | 8.83% | $587.40B | May 9, 2025 | ▼ 484.4K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 14.69M | 7.81% | 7.81% | $519.52B | May 2, 2025 | ▼ 27.2K |
FARALLON CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 13.53M | 7.19% | 7.19% | $478.59B | May 15, 2025 | ▲ 286.0K |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 11.79M | 6.27% | 6.27% | $416.82B | May 13, 2025 | ▲ 966.2K |
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 10.19M | 5.42% | 5.42% | $380.57B | May 15, 2025 | ▲ 706.1K |
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 7.94M | 4.22% | 4.22% | $280.65B | May 15, 2025 | — held |
NEXTECH INVEST, LTD. biological products, (no diagnostic substances) | 7.60M | 4.04% | 4.04% | $268.77B | May 15, 2025 | NEW |
FMR LLC biological products, (no diagnostic substances) | 7.54M | 4.01% | 4.01% | $266.46B | May 12, 2025 | ▲ 793.7K |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 6.18M | 3.28% | 3.28% | $218.46B | May 15, 2025 | ▼ 375.0K |
STATE STREET CORP biological products, (no diagnostic substances) | 5.80M | 3.09% | 3.09% | $205.26B | May 15, 2025 | ▲ 13.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
23
Increased
+7.11M shares5
New Positions
first time holders16
Decreased
−5.23M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.88M
+7.11M / −5.23M
Net new holders
+12
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RVMD insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
11
Sell transactions
0.36
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Mancini Anthony See Remarks | May 26, 2026 | Sale | 700 | $153.30 | $107.3K | 56.8K | Form 4 ↗ |
Mancini Anthony See Remarks | May 26, 2026 | Sale | 2,000 | $154.06 | $308.1K | 54.8K | Form 4 ↗ |
Mancini Anthony See Remarks | May 26, 2026 | Sale | 421 | $154.82 | $65.2K | 54.4K | Form 4 ↗ |
Mancini Anthony See Remarks | Apr 27, 2026 | Sale | 1,671 | $131.66 | $220.0K | 55.8K | Form 4 ↗ |
Mancini Anthony See Remarks | Apr 27, 2026 | Sale | 1,049 | $132.88 | $139.4K | 54.8K | Form 4 ↗ |
Mancini Anthony See Remarks | Apr 27, 2026 | Sale | 400 | $134.34 | $53.7K | 54.4K | Form 4 ↗ |
GOLDSMITH MARK A See Remarks | Apr 15, 2026 | Sale | 120,000 | $150.09 | $18.01M | 276.7K | Form 4 ↗ |
Mancini Anthony See Remarks | Mar 25, 2026 | Sale | 1,800 | $93.22 | $167.8K | 90.0K | Form 4 ↗ |
Mancini Anthony See Remarks | Mar 25, 2026 | Sale | 3,128 | $94.16 | $294.5K | 86.9K | Form 4 ↗ |
Mancini Anthony See Remarks | Mar 25, 2026 | Sale | 21,086 | $95.49 | $2.01M | 65.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Revolution Medicines, Inc. (RVMD) is primarily owned by institutional investors, who hold approximately 90.5% of total shares outstanding. Company insiders own approximately 10.46%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Revolution Medicines, Inc. is VANGUARD GROUP INC, holding approximately 16.61 million shares — equal to 8.83% of outstanding shares — as of March 31, 2025.
A total of 297 institutional investors currently hold RVMD stock, with a combined institutional value of approximately $6.83 billion as of the most recent 13F filing period.
Frequently asked questions
RVMD ownershipRevolution Medicines, Inc. (RVMD) is primarily owned by institutional investors, who hold approximately 90.5% of shares. The largest shareholder is VANGUARD GROUP INC with a 8.83% stake. Company insiders hold 10.46%. Data sourced from SEC Form 13F as of March 31, 2025.